Почетна › Рак јетре (хепатоцелуларни карцином) › Ilinois
Kliničke studije za Рак јетре (хепатоцелуларни карцином) u državi Ilinois
21 studija za Рак јетре (хепатоцелуларни карцином) traži učesnike na lokacijama u državi Ilinois.
Gradovi u državi Ilinois
Zvanični tekst studije (na engleskom)
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
- OSF St. Francis Medical Center, Peoria
Тражи се учесникФаза 2
Узраст од 18 до 100 · Оба пола · Ажурирано 10. 11. 2026. · NCT07219459Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
- RUSH University Medical Center, Chicago
- University of Chicago, Chicago
Тражи се учесникОпсервациона студија
Узраст 22 и старији · Оба пола · Ажурирано 6. 11. 2026. · NCT06486454A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
- Clinical Trial Site, Chicago
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 27. 10. 2026. · NCT06600321A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Orchard Healthcare Research Inc, Skokie
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT06330064Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer
- Northwestern University, Chicago
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT07042919A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
- Local Institution - 0107, Chicago
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT07291076Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- Northwestern Medicine - Northwestern Memorial Hospital /ID# 257378, Chicago
- University of Chicago Medical Center /ID# 258197, Chicago
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 14. 10. 2026. · NCT06084481Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Research Site, Chicago
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT06921785Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
- Memorial Hospital, Shiloh
- Siteman Cancer Center - Shiloh, Shiloh
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 8. 10. 2026. · NCT07227012Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #26, Chicago
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 1. 10. 2026. · NCT05176483National Liver Cancer Screening Trial
- Northwestern University, Chicago
Тражи се учесникФаза 4
Узраст од 18 до 85 · Оба пола · Ажурирано 25. 9. 2026. · NCT06084234A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- City of Hope Chicago Cancer Center, Zion
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 16. 9. 2026. · NCT06427941Defining the Ablative Dose for Y-90 TARE
- Northwestern University, Chicago
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 15. 9. 2026. · NCT07586046Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Lurie Children's Hospital-Chicago, Chicago
Тражи се учесникФаза 1/2
12 Months – 30 Years · Оба пола · Ажурирано 25. 8. 2026. · NCT04851119Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- Carle at The Riverfront, Danville
- и још 6
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 17. 8. 2026. · NCT07166406Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
- University of Chicago Comprehensive Cancer Center, Chicago
- Carle Cancer Center NCI Community Oncology Research Program, Urbana
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 4. 8. 2026. · NCT05168163DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.
- Rush University Medical Center, Chicago
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 21. 7. 2026. · NCT07717437Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
- Northwestern University, Chicago
- Northwestern Medicine Kishwaukee Hospital, DeKalb
- Northwestern Medicine Delnor Hospital, Geneva
- и још 4
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 26. 5. 2026. · NCT05620771Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
- University of Chicago Medical Center, Chicago
- Methodist Medical Center of Illinois, Peoria
Тражи се учесникФаза 4
Узраст од 18 до 64 · Оба пола · Ажурирано 22. 1. 2026. · NCT04373564SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chicago
Тражи се учесникОпсервациона студија
Сви узрасти · Оба пола · Ажурирано 28. 10. 2025. · NCT03452774The Dragon PLC Trial (DRAGON-PLC)
- Rush University Medical Center, Chicago
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 15. 5. 2025. · NCT06914648Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.